One in every five generic medicines reaching patients worldwide now comes from India — and Odisha Chief Minister Mohan Charan Majhi wants that number front and centre in the national conversation. On Tuesday, October 13, 2026, Majhi took to X to frame India's pharmaceutical output not just as an economic achievement, but as a moral one: a country that refuses to leave the world's sick behind.

How India Became the World's Pharmacy

The story did not begin overnight. India's dominance in generic drug manufacturing traces directly to the landmark Patents Act of 1970, which permitted process patents rather than product patents — a deliberate policy choice that let Indian manufacturers replicate molecules cheaply and legally. That legal architecture seeded a domestic industry that would, decades later, supply antiretrovirals to sub-Saharan Africa and paracetamol to pharmacies from Lagos to Lima.

By the 2000s, the phrase 'pharmacy of the world' — India's global identity in health diplomacy — had moved from aspiration to established fact, anchored by massive export volumes of essential and life-saving drugs to developing nations at prices Western manufacturers could not match.

Janaushadhi Scheme and the Domestic Dividend

The same logic that made India a global supplier has been turned inward through the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, launched in 2015, which rolls out dedicated generic-medicine outlets across the country at steep discounts to branded equivalents. The scheme represents the domestic face of a philosophy Majhi is amplifying today: that affordable medicine is a right, not a privilege, whether the patient is in rural Odisha or rural Kenya.

Successive governments have linked India's pharmaceutical strength to two simultaneous goals — hard export earnings and soft-power leadership on global health equity. Majhi's post fits squarely within that dual narrative, associating the BJP's governance record with both.

What the Statistic Signals

The claim of one-in-five generics is a striking marker of scale. India's pharmaceutical export orientation is well documented — a large domestic manufacturing base, cost-competitive chemistry talent, and regulatory approvals from agencies across Europe, the United States, and Africa have together made Indian generics the default affordable option in dozens of formularies worldwide. For a state-level leader like Majhi, invoking a global health statistic is also a quiet assertion: Odisha, and states like it, are part of an industrial supply chain that reaches every continent.

The kicker is this: as the next generation of blockbuster drugs approaches patent cliffs, the world will need generic alternatives faster than ever — and the country best positioned to supply them, cheaply and at scale, is still India.